U.S. Dermal Fillers Market Size, Share & COVID-19 Impact Analysis, By Material (Hyaluronic Acid, Calcium Hydroxylapatite, Poly-L-lactic Acid, PMMA (Poly (methyl methacrylate)), Fat Fillers, and Others), By Product (Biodegradable and Non-biodegradable), By Application (Scar Treatment, Wrinkle Correction Treatment, Lip Enhancement, Restoration of Volume/Fullness, and Others), By End-user (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others), and Forecast, 2022-2029

The U.S. dermal fillers market size was valued at USD 2.13 billion in 2021 and is projected to grow from USD 2.24 billion in 2022 to USD 3.61 billion by 2029, exhibiting a CAGR of 7.1% during the forecast period. Based on our analysis, the market exhibited a decline of -31.2 % in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with dermal fillers experiencing lower-than-anticipated demand in the U.S. compared to pre-pandemic levels.

Over time, a surge in demand for cosmetic procedures had been witnessed among the U.S. population. Non-invasive procedures such as dermal fillers are injected into the skin to achieve favorable outcomes. The advantages associated with these products such as treatment of acne scars, wrinkle correction, facial line correction, lip enhancement, and restoration of volume augment their demand among individuals. Furthermore, the rise of disposable income in the U.S. and the growing awareness among people regarding these procedures is expected to boost procedure volume.    

Positive trends in the market led significant companies to introduce new products, offering improved aesthetic outcomes post several research and development strategies. These launches are expected to provide new growth avenues to the market during the forecast period. Therefore, high demand accompanied with growing R&D initiatives to launch products with a wide range of applications contributes to the growth of the market.

COVID-19 IMPACT

Market Negatively Impacted Due to Cancellation & Postponement of Elective Procedures

The effect of the pandemic was evident in the U.S. healthcare system as it experienced a differing impact during the unprecedented crisis. Preventive steps such as lockdown restrictions imposed in the country to curb the spread of the virus led to the market decline. These led to a strong negative impact on dermal filler procedures as dermatology clinics were closed during this period.

Elective procedures, such as cosmetic and aesthetic procedures, were canceled or postponed creating a negative impact on the market. Supply chain disruptions due to limitations in import & export led to reduced production, which also contributed toward the decline of the market. Some of the key players in the market with a strong portfolio of products also accounted for less revenue due to disruption in their manufacturing and supply chain operations, which was followed by decreased demand for their key products among customers.  

• For example, Juvederm’s revenue in the U.S. reduced by 45.9% compared to previous year. The product accounted for USD 318.0 million in 2020, which is comparably less than its 2019 revenue, i.e. USD 587.5 million.

In 2021, the market witnessed substantial growth as restrictions related to the pandemic were lifted and healthcare activities resumed to the normal pace. The increased awareness among adults regarding their appearances during the lockdown also led to the increase in aesthetic procedures, which contributed positively toward the U.S. dermal fillers market growth. Key companies such as Revance Therapeutics and AbbVie Inc. experienced an increase in their aesthetic portfolio. This was due to the increased number of procedures reported by cosmetic and plastic surgeons in the U.S.

• For instance, Revance Therapeutics announced that the company earned USD 70.8 million in 2021 for its RHA collection of these fillers. The company witnessed an increase in revenues by around 448.8% in comparison to previous year.


• In a similar way, increasing investment by AbbVie Inc. toward improving their brand presence led to a growth of more than 100.0% in their net revenues of Juvederm collection in 2021 as compared to the previous year.

LATEST TRENDS

Industry Value to be Impelled by Increasing Adoption of Cannulas for Dermal Filler Procedures

In the past few years, the popularity of cosmetic fillers has increased. Previously, these products were administered through sharp hypodermic needles. However, currently, new blunt tipped needles known as microcannulas have gained popularity.

The size and shape of the cannulas lead to single point entry, which reduces the number of injections along with treating a large area at one time. This leads to less painful procedures compared to sharp hypodermic needles.

Another advantage associated with microcannulas is that its blunt tip may displace a blood vessel rather than lacerating it and causing skin necrosis during a procedure. Due to such advantages, the U.S. FDA approved certain microcannulas, which can be used to administer dermal fillers.

• For instance, in October 2019, the U.S. FDA approved the use of TSK STERiGLIDE cannula for the administration of Juvederm Voluma XC for the treatment of mid-face age related volume deficit in adults of age over 21.

These new trends in this market lead to more adoption of these procedures, which will fuel the market growth.

DRIVING FACTORS

Market Expansion to be Driven by Increasing Demand for Minimally Invasive Cosmetic Procedures

An important factor that drives the market growth is the growing demand for minimally invasive and non-invasive procedures among the population. The adoption of procedures such as dermal filler injections has surged tremendously over the past decade due to the rising inclination of people toward hassle-free and pain-free methods to improve their aesthetic appearance.  

• For example, according to the statistics published by the American Society of Plastic Surgeons (ASPS), post pandemic, there has been a significant growth of around 200% in minimally invasive procedures performed globally.  

The growing number of procedures also influenced major market players to launch technologically advanced solutions to cater to the increasing demand. Therefore, the increasing demand for minimally-invasive procedures among the U.S. population lead to the launch of new products, which augments the market growth.

• In December 2021, the U.S. FDA granted approval to Teoxane SA for the launch of its new dermal filler product, RHA Redensity’s first edition for the treatment of moderate to severe dynamic perioral rhytids in adults aged 22 or older.

Industry Value to Rise Due to Increasing Number of Dermal Filler Procedures Coupled with Latest R&D Initiatives

Dermal fillers have been approved in the U.S. for the treatment of several aesthetic applications such as the treatment of moderate-to-severe facial wrinkles, increasing fullness of lips, restoration of volume in cheek and chin and treatment of cheek acne scars. These procedures are considered as one of the most frequent non-surgical aesthetic procedures performed in the U.S. 

• According to the 2020 statistics published by the International Society of Aesthetic Plastic Surgery (ISAPS), a total of 807,870 hyaluronic acid procedures were performed in the U.S. in 2020.

Therefore, the increasing number of dermal filler procedures for the treatment of the aforementioned complications fuels the market growth.

Furthermore, focus of major players toward research and development initiatives to expand the aesthetic use of their dermal filler products also contributes toward the growth of the market.

• For instance, in August 2022, GALDERMA announced that the company is conducting a clinical trial for their investigational product GP0109, a hyaluronic acid filler for the augmentation and correction or retrusion in the chin region.

The growing number of procedures and the clinical trials conducted by key players to fulfill the demand of the U.S. population is expected to fuel the market growth.

RESTRAINING FACTORS

Side Effects and High Cost Related to Dermal Filler Procedures is Limiting the Demand for these Products

Dermal fillers have multiple aesthetic applications. Regardless of that, there are several factors which limit the growth of the market in the U.S. Comparatively, higher cost of these products and procedures is among the leading factors limiting the demand, especially from emerging countries.

• For instance, the cost of the hyaluronic acid filler (Juvederm Ultra, Juvederm Ultra Plus, Perlane, Restylane, Belotero) is around USD 550.0-850.0 and that of fat grafting is around USD 2,000-3,000.

Furthermore, due to the biodegradable nature of most of these products, patients are expected to have repeated and constant treatments to maintain their appearances. This increases the economic strain on the patient, leading to lower adoption of these procedures. Insurance companies may not extend insurance coverage to these cosmetic procedures, which further increases the economic cost for the customers.

Combined with the high cost, side effects caused by the fillers is also a major factor which hinders the adoption of the products. The possible adverse effects which can be witnessed include swelling, redness, bruising at the injection site, pain, lumps & bumps, and infections. Furthermore, rare adverse reactions such as blurred vision, tissue scarring, and blindness, among others can occur if the dermal filler is inadvertently injected into a blood vessel. Therefore, these factors can restrain the growth of this market in the future.

SEGMENTATION

By Material Analysis

To know how our report can help streamline your business, Speak to Analyst

Hyaluronic Acid Segment to Record Appreciable Growth Due to Increasing Launch of New Products

On account of material, the market is segmented into calcium hydroxylapatite, poly-l-lactic acid, hyaluronic acid, fat fillers, PMMA (poly (methyl methacrylate)), and others. The hyaluronic acid segment dominates the market as the product is considered as the gold standard of dermal fillers. Furthermore, launch of multiple products in this segment is anticipated to drive the growth.  

• For instance, in May 2020, the U.S. FDA provided approval to GALDERMA for the launch of Restylane Kysse for the correction of upper perioral rhytids (wrinkles around upper lips) and for lip augmentation in adults over the age of 21.

The calcium hydroxylapatite (CaHA) segment accounts for a significant share as it is comparatively safer than other products. CaHA is a long-lasting product and has a thicker consistency than hyaluronic acid. It is a non-permanent filler but is highly biocompatible with human tissues, which increase its demand among individuals.

• For instance, in October 2021, the U.S. FDA approved Merz Aesthetics Radiesse (+), lidocaine injectable implants for deep injection which can be used to improve moderate to severe loss of jawline contour.

The PMMA (Poly (methyl methacrylate)) segment accounts for a lesser share in the market as it is non-biodegradable in nature thus, limiting its adoption among individuals.

The Poly-l-lactic acid segment is anticipated to witness considerable growth due to re-launch of products during the forecast period.  

By Product Analysis

Biodegradable Segment Share to Rise Due to Significant Surge in Product Adoption

By product, the market is divided into biodegradable and non-biodegradable. The dominant share is held by the biodegradable segment due to wide availability of products and associated benefits such as safety and efficacy. Furthermore, these products are approved for a maximum number of aesthetic applications, which contributes to the segmental growth.

The non-biodegradable products witness a slow growth in the market due to the rising preference of customers toward biodegradable products. As these products were non-decomposable, they are permanent in nature. Clinical disadvantages of these solutions, as compared to the biodegradable products is among the leading factors for the comparatively lower preferred toward these products in the U.S.

By Application Analysis

Growing Investments in R&D Initiatives to Launch Products for Wrinkle Correction to Fuel Wrinkle Correction Segmental Growth 

By application, the market is segregated into wrinkle correction treatment, lip enhancement, scar treatment, restoration of volume/fullness, and others. The wrinkle correction segment is expected to register a comparatively higher CAGR during the forecast period. This is due to the increasing investments for extensive research and development of these fillers for wrinkle correction.

• In August 2020, Revance Therapeutics, Inc. announced the launch of RHA Dermal Filler Line, the first and only FDA-approved dermal fillers for correction of dynamic facial wrinkles and folds in the U.S.

A substantial share of the market is also held by the lip enhancement segment as the number of lip procedures in the country has increased. The growing need for aesthetic lip improvements is driven by the launch of non-invasive aesthetic products, leading to the segment’s growth.

• For instance, in April 2018, Merz Pharma launched Belotero Lips developed for the treatment of perioral lines and lip enhancement.

The third-largest segment in the market is restoration of the volume/fullness segment due to recent launches such as JUVEDERM VOLUX by Allergan Aesthetics. Scar treatment is estimated to have a lower share in the market during the forecast period.

By End-user Analysis

Specialty and Dermatology Clinics Segment to Register Lucrative Growth Due to Strong Patient Volumes

By end-user, the market is divided into specialty & dermatology clinics, hospitals & clinics, and others.

The specialty & dermatology clinics segment is projected to account for the highest share in the market during the forecast period. This segmental dominance is due to the growing number of dermal filler procedures in such facilities. Furthermore, the rising number of procedures for scar treatment and wrinkle correction is expected to favor the expansion of the segment.  

• For instance, according to the American Society of Plastic Surgeons (ASPS), 3.4 million soft tissue filler procedures were performed in 2020 alone. Such strong procedural trends are anticipated to boost the segment growth during the forecast period.

Hospitals & clinics segment holds a significant share as numerous dermal filler procedures are conducted in hospitals.

• For instance, according to the American Society of Plastic Surgeons (ASPS), in 2020, approximately 18.0% of cosmetic procedures are performed in hospitals. Such strong cosmetic surgery procedural trends in hospitals are anticipated to contribute to the segment’s growth prospects.

KEY INDUSTRY PLAYERS

Market Players Provide Strong Product Portfolio to Strengthen their Position

In terms of the competitive landscape, the U.S. market has companies ranging from established and large players to emerging players. In the present scenario, the U.S. market was dominated by AbbVie Inc. with a significant proportion. The company’s robust portfolio of products all-inclusive of a collection of hyaluronic acid fillers known as JUVEDERM led to the dominance of the company. Moreover, multiple applications of JUVEDERM collection also contribute strongly toward the company’s peak position in the U.S. market.

Some of the other companies with a considerable presence in the U.S. market include Merz Pharma and Revance Therapeutics, Inc. Strategic initiatives by the companies such as participating in conferences and conducting trials to analyze the safety and effectiveness of its key products lead to the growth of the players in the U.S. market.

• In September 2021, Revance Therapeutics, Inc. highlighted the key findings from their new post-hoc subgroup analysis evaluating the effectiveness and safety of the RHA dermal fillers for the correction of moderate-to-severe nasolabial folds (NLFs) in patients with darker skin color. The findings were unveiled during the 2021 Virtual Skin and Color Update meeting.

Furthermore, other companies such as Prollenium Medical Technologies and GALDERMA are launching new products to expand their presence in the U.S. market. 

LIST OF KEY COMPANIES PROFILED:

• Allergan Aesthetics (AbbVie Inc.) (U.S.)


• Revance Therapeutics, Inc. (U.S.)


• Merz Pharma (Germany)


• GALDERMA (Switzerland)


• Suneva Medical (U.S.)


• Prollenium Medical Technologies (Canada)


• Bioxis pharmaceuticals (France)


• Sinclair (U.K.)

KEY INDUSTRY DEVELOPMENTS:

• February 2022: Allergan Aesthetics’ JUVÉDERM VOLBELLA XC received approval from the U.S. FDA for improving infraorbital hollows in adults in the age group of 21 and above.


• February 2022: Merz Aesthetics launched Radiesse (+) Lidocaine injectable. Radiesse Injectables is the first and only CaHA (calcium hydroxylapatite) portfolio in the U.S. Also, Radiesse (+) is the only FDA-approved injectable for the improvement of jawline contour.


• March 2022: Galderma presented clinical data on their hyaluronic acid dermal filler range at AMWC (Aesthetic & Anti-Aging Medicine World Congress). The company presented data for Alluzience and Sculptra.


• November 2021: Galderma received U.S. FDA approval for Restylane Defyne for chin augmentation.


• September 2020: Prollenium Medical Technologies, Inc. received the FDA approval of Revanesse Lips+ for lips to temporarily add volume and fullness in adults 22 years of age or older.

REPORT COVERAGE

An Infographic Representation of U.S. Dermal Fillers Market

View Full Infographic

To get information on various segments, share your queries with us

The U.S. dermal fillers market research report provides a detailed market analysis. It focuses on key aspects such as an overview of the number of procedures in the U.S., overview of the pricing analysis of types of products, insights regarding the regulatory scenario in the U.S., overview of the reimbursement scenario in the U.S., insights regarding the pipeline products, new product launches, and the impact of COVID-19 on the market. Besides this, the report also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation